Stockreport

iBio Details Generative AI Antigen Platform to Speed GPCR Antibody Discovery and Close “Trust Gap” [Yahoo! Finance]

iBio, Inc.  (IBIO) 
NASDAQ:AMEX Investor Relations: ir.ibioinc.com
PDF design water-soluble, stable engineered epitopes as "personalized baits" aimed at steering antibody discovery toward specific targets and shortening timelines (e.g., IBI [Read more]